Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
ACA, addressed, ADHF, announced, antiapoptopic, artery, back, Bioserve, blind, budgetary, CABG, calcium, calendar, Canada, cardiac, cardioprotection, Carlo, carryforward, channel, consumption, contractility, coronary, covenant, curve, daily, DCRI, decompensated, designee, disallowance, distinction, dobutamine, dosage, double, Doug, earliest, ejection, exceed, Fast, Finland, Finnish, forma, fraction, frequently, guideline, Hay, healthcare, hemodynamic, ICH, inferred, infusion, intervening, intracellular, intracerebral, John, Kelley, Kelly, largest, left, levosimedan, levosimendan, licensee, lifted, Lifting, lt, LVEF, median, mediated, mitochondrial, mitral, Monte, morbidity, mortality, myocardial, Newco, noncash, nonclinical, Orion, output, outsourced, perfusion, Pharma, PhD, phosphodiesterase, physiologic, potassium, pro, probe, Proehl, provisional, qualitative, quantitative, Randall, randomized, reassessed, recapitalization, relaxation, remove, resale, rhythm, road, route, satisfactorily, sensitization, sensitizer, Simdax, solution, subsidiary, subtracting, suggest, tangible, tiered, Track, troponin, unaudited, underwritten, validly, valve, vasodilation, ventricular, vial, waiver, wholly, world
Removed:
AABB, acceleration, accomplishing, accrue, added, adulterated, anemia, apparent, arising, assisted, assuming, attendance, avenue, aware, bandage, batch, bekaert, biennial, binding, bioavailability, biosensor, borne, burden, capacity, capitalize, cherry, chronic, cited, Col, Collection, combining, community, compatibility, complicated, conclude, consultant, contemplate, counsel, CRO, death, delivering, dermatologic, detect, device, devoted, direction, disappointing, disclosing, discretion, domestic, donated, donor, doubt, dysfunction, earlier, economically, Efficient, emergency, Engle, enhancing, enterprise, environment, enzyme, epithelial, Europe, excise, exclusively, exist, existence, expanded, explanatory, Extending, Eye, facilitate, facilitating, faster, feasibility, Florida, fluid, Fluorovent, formation, formulated, formulator, generated, geographic, glucose, healthy, hired, hydrogen, ideal, identifying, implant, impracticable, inactive, inadequately, incorrectly, indemnification, India, ingredient, initiative, instrument, intense, Interactive, internally, IRC, ischemic, joint, kind, Klein, larger, learned, led, listing, LLC, lot, lung, maker, matter, measuring, Melixia, Melville, methodology, modification, moist, monitored, nationwide, necessity, Obama, online, ordinary, organ, orphan, overhead, passed, people, percent, permanent, plastic, population, predicate, premium, prescribed, presence, presently, preventive, PrimaPharm, print, procurement, pronouncement, proposed, prototype, qualifying, realizing, recast, receivable, recipient, reciprocal, recognize, recommended, red, reformulated, reimbursing, remediated, render, replacement, reportable, request, requirement, respiratory, restoring, rosacea, Sarasota, satisfy, scar, scrap, sector, segment, segmented, senior, shipment, showed, skeptical, skepticism, smaller, SMP, sought, South, Southern, Stern, structure, substitute, Swissmedic, target, taxed, tolerated, topically, toxicity, transfused, trauma, turn, typing, unchanged, undergo, universal, unsecured, venture, vi, view, virtually, warning, wording, worked, writing
Filing tables
Filing exhibits
TENX similar filings
Filing view
External links
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the incorporation by reference in the Registration Statement of Oxygen Biotherapeutics, Inc. (the “Company”) on Form S-8 (No. 333-196464), on Form S-3 (No. 333-196468) and on Form S-3 (No. 333-191579) of our report, dated July 29, 2014, relating to the consolidated financial statements of the Company which appear in this Form 10-K as of April 30, 2014.
/s/ CHERRY BEKAERT LLP
Raleigh, North Carolina
July 29, 2014